PROVO, Utah, Feb. 5, 2015 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE: NUS) today announced fourth-quarter results with revenue of $609.6 million, the top end of the company's guidance, compared to $1.06 billion in the prior-year period. Revenue in the fourth quarter of 2013 was augmented by $350 million in limited-time offer sales of the ageLOC TR90 weight management system. Revenue for the quarter was negatively impacted 4 percent by foreign currency fluctuations. Earnings per share for the quarter were at the top end of guidance at $0.77, versus $2.02 in the prior-year period. Earnings per share for the quarter were negatively impacted $0.08 by prepayment fees associated with the refinancing of the company's debt, and $0.06 by foreign currency translation expense.

The company reported full-year 2014 revenue of $2.57 billion, a 19 percent year-over-year decline. Annual revenue was negatively impacted 3 percent by foreign currency fluctuations. Earnings per share for the year were $3.11 compared to $5.94 in 2013.

"Our business performed as we expected for the quarter, and we look forward to a solid 2015," said Truman Hunt, president and chief executive officer. "As we review the year, three factors impacted our results. First, our year-over-year comparisons were especially challenging considering that we were lapping a $550 million TR90 launch in the second half of 2013, our largest product introduction. Second, a strengthening U.S. dollar negatively impacted revenue by more than $100 million in 2014, and by $24 million sequentially from the third to the fourth quarter. Third, the proactive steps we took early in 2014 in Mainland China to address a regulatory review impacted revenue significantly, although we stabilized revenue from the second to the fourth quarter. Despite the 2014 revenue decline, our three-year compounded annual revenue growth rate was 14 percent, reflecting longer-term business improvement."


                                                     Regional Results

                       The company's regional revenue results are presented in the following table.

                         Revenue Results for the Fourth Quarters Ended December 31, 2014 and 2013

                                                      (in thousands)

                                       2014                             2013                        %Change       Constant Currency
                                                                                                                    % Change
                                                                                                                    --------


    Greater China                  $212,981                         $481,561                                (56%)                   (55%)

    North Asia                      186,041                          286,288                                (35%)                   (30%)

    Americas                         82,470                          126,149                                (35%)                   (14%)

    South Asia/Pacific               86,626                           99,477                                (13%)                    (9%)

    EMEA                             41,489                           62,311                                (33%)                   (32%)
                                     ------                           ------


    Total                          $609,607                       $1,055,786                                (42%)                   (38%)
                                   ========                       ==========


                                         The company's regional Actives and Sales Leaders statistics are presented in the following table.

                                                         Actives/Sales Leaders Statistics as of December 31, 2014 and 2013


                                    2014                        2013                       % Increase (Decrease)
                                    ----                        ----                       --------------------

                       Actives                  Sales Leaders                                   Actives                                   Sales Leaders         Actives         Sales Leaders
                       -------                  -------------                                   -------                                   -------------         -------         -------------


    Greater China                393,000                      24,537                                         490,000                                     61,546         (19.8%)               (60.1%)

    North Asia                   391,000                      17,478                                         409,000                                     19,816          (4.4%)               (11.8%)

    Americas                     186,000                       7,471                                         193,000                                      8,274          (3.6%)                (9.7%)

    South Asia/Pacific           124,000                       8,458                                         120,000                                      7,992            3.3%                  5.8%

    EMEA                         114,000                       4,065                                         123,000                                      4,489          (7.3%)                (9.4%)
                                 -------                       -----                                         -------                                      -----


    Total                      1,208,000                      62,009                                       1,335,000                                    102,117          (9.5%)               (39.3%)
                               =========                      ======                                       =========                                    =======



    "Actives" are persons who
     purchased products directly from
     the company during the previous
     three months.



    "Sales Leaders" are independent
     distributors, and sales
     employees, contractual sales
     promoters and independent
     marketers in China, who achieve
     certain qualification
     requirements.

Operational Performance

The company's comparable financial results were significantly impacted by the large revenue and selling expenses generated from the fourth-quarter 2013 launch of TR90. Operating margin was 15.0 percent for the quarter, compared to 17.9 percent in the fourth quarter of 2013. Gross margin during the quarter was 82.5 percent, versus 84.4 percent in the prior-year period. Selling expenses were 42.1 percent of sales in the fourth quarter, compared to 48.2 percent in the prior-year period. General and administrative expenses were 25.4 percent of sales compared to 18.3 percent in the prior-year period. The company's effective income tax rate for the quarter was 38.1 percent, compared to 34.8 percent in the prior year, due primarily to a non-deductible currency charge related to Venezuela earlier in the year. Cash and current investments at the end of the quarter were $300.2 million and debt was $247.3 million. Dividend payments during the quarter were $20.4 million. Cash flow from operations for the quarter were approximately $90 million, and the company repurchased $20.7 million of its outstanding shares, leaving $348.8 million in the company's repurchase authorization.

Outlook

"We believe we are on course to renew constant-currency growth in 2015," said Hunt. "We look forward to introducing new anti-aging products in both the nutrition and skin care categories during the second half of the year. On the nutrition front, we plan to introduce ageLOC Youth, our most advanced anti-aging supplement. We also plan to introduce ageLOC Me, an innovative anti-aging skin care system that enables consumers to personalize a daily regimen based on individual preferences and skin care needs. In the Americas and Greater China we plan to launch our new essential oil lines. Early sales leader enthusiasm, encouraging consumer testing, and the size of each of these product categories lead us to believe these products will be important business drivers," concluded Hunt.

"The fundamentals of the business are improving, and we continue to anticipate constant-currency growth in 2015," said Ritch Wood, chief financial officer. "Foreign currency continues to weigh on our results, and we typically see a seasonal revenue decline from the fourth quarter to the first quarter. Consequently, we anticipate first-quarter revenue of $530 to $550 million, which includes a negative foreign currency impact of approximately $50 million, and first-quarter earnings per share of $0.70 to $0.74. Our full year 2015 revenue and earnings guidance remains consistent with prior guidance of $2.50 billion to $2.56 billion and $3.80 to $4.00 per share, respectively."

The Nu Skin management team will host a conference call with the investment community on Feb. 5, 2015, at 11 a.m. (EST). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com. A replay of the webcast will be available at the same URL through Feb. 20, 2015.

About Nu Skin Enterprises, Inc.
Nu Skin Enterprises, Inc. demonstrates its tradition of innovation through its comprehensive anti-aging product portfolio, independent business opportunity and corporate social responsibility initiatives. The company's scientific leadership in both skin care and nutrition has established Nu Skin as a premier anti-aging company. The company's anti-aging products feature the new ageLOC(®) line of products including ageLOC(®) Tru Face(®) Essence Ultra firming serum, the ageLOC(®) TR90(®) weight management and body shaping system, ageLOC(®) R(2) nutritional supplement, and ageLOC(®) Transformation daily skin care system. A global direct selling company, Nu Skin operates in 53 markets worldwide and is traded on the New York Stock Exchange under the symbol "NUS." More information is available at http://www.nuskin.com.

Please Note: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations regarding the company's performance, growth and new product introductions; projections regarding revenue, earnings per share, foreign currency fluctuations and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "project," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "could," "may," "might," the negative of these words and other similar words.

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:


    --  risk that continuing media and regulatory scrutiny and investigations in
        China, and any actions taken by the company or by regulators, could
        cause unanticipated complications or other difficulties, could make it
        more difficult to forecast results for future periods, and could
        negatively impact the company's revenue, sales force and business in
        this market, including the interruption of sales activities, loss of
        licenses, the imposition of fines, and any other adverse actions or
        events;
    --  risks related to negative publicity regarding media allegations and
        subsequent regulatory investigations and fines;
    --  risk that direct selling regulations in China may be modified,
        interpreted or enforced in a manner that results in negative changes to
        our business model or the imposition of a range of potential penalties;
    --  any failure of current or planned initiatives or products to generate
        interest among our sales force and customers and generate sponsoring and
        selling activities on a sustained basis;
    --  risks related to accurately predicting, delivering or maintaining
        sufficient quantities of products to support our planned initiatives or
        launch strategies, and increased risk of inventory write-offs if we
        over-forecast demand for a product or change our planned initiatives or
        launch strategies;
    --  risk of foreign currency fluctuations and the currency translation
        impact on the company's business associated with these fluctuations;
    --  unpredictable economic conditions and events globally;
    --  regulatory risks associated with the company's products, which could
        require the company to modify its claims or inhibit the company's
        ability to import or continue selling a product in a market if it is
        determined to be a medical device or if it is unable to register the
        product in a timely manner under applicable regulatory requirements;
    --  adverse publicity related to the company's business, products, industry
        or any legal actions or complaints by the company's sales force or
        others;
    --  any prospective or retrospective increases in duties on the company's
        products imported into the company's markets outside of the United
        States and any adverse results of tax audits or unfavorable changes to
        tax laws in the company's various markets; and
    --  continued competitive pressures in the company's markets.

The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company's beliefs as of the date that such information was first provided and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.



                             NU SKIN ENTERPRISES, INC.

                   Consolidated Statements of Income (Unaudited)

             For the Fourth Quarters Ended December 31, 2014 and 2013

                     (in thousands, except per share amounts)


                                                                 2014      2013
                                                                 ----      ----

    Revenue:

            Greater China                                    $212,981  $481,561

            North Asia                                        186,041   286,288

            Americas                                           82,470   126,149

            South Asia/Pacific                                 86,626    99,477

            Europe                                             41,489    62,311
                                                               ------    ------

    Total revenue                                             609,607 1,055,786


    Cost of sales                                             106,505   164,672
                                                              -------   -------


    Gross profit                                              503,102   891,114
                                                              -------   -------


    Operating expenses:

            Selling expenses                                  256,693   508,846

            General and administrative expenses               155,111   193,673
                                                              -------   -------

    Total operating expenses                                  411,804   702,519
                                                              -------   -------


    Operating income                                           91,298   188,595


    Other (expense)/income, net                              (16,127)    3,399
                                                              -------     -----

    Income before provision for income
     taxes                                                     75,171   191,994

    Provision for income taxes                                 28,664    66,723
                                                               ------    ------


    Net income                                                $46,507  $125,271
                                                              =======  ========


    Net income per share:

            Basic                                               $0.79     $2.13

            Diluted                                             $0.77     $2.02


    Weighted average common shares outstanding:

            Basic                                              59,117    58,791

            Diluted                                            60,442    61,881


                             NU SKIN ENTERPRISES, INC.

                   Consolidated Statements of Income (Unaudited)

                  For the Years Ended December 31, 2014 and 2013

                     (in thousands, except per share amounts)


                                                                 2014       2013
                                                                 ----       ----

    Revenue:

            Greater China                                    $948,523 $1,363,182

            North Asia                                        782,985    869,400

            Americas                                          329,027    370,087

            South Asia/Pacific                                328,388    378,988

            Europe                                            180,572    195,061
                                                              -------    -------


    Total revenue                                           2,569,495  3,176,718


    Cost of sales                                             478,434    505,806
                                                              -------    -------


    Gross profit                                            2,091,061  2,670,912
                                                            ---------  ---------


    Operating expenses:

            Selling expenses                                1,116,572  1,476,772

            General and administrative expenses               622,301    640,028
                                                              -------    -------

    Total operating expenses                                1,738,873  2,116,800
                                                            ---------  ---------


    Operating income                                          352,188    554,112


    Other (expense)/income, net                              (53,681)     2,828
                                                              -------      -----

    Income before provision for income
     taxes                                                    298,507    556,940

    Provision for income taxes                                109,331    192,052
                                                              -------    -------


    Net income                                               $189,176   $364,888
                                                             ========   ========


    Net income per share:

            Basic                                               $3.20      $6.23

            Diluted                                             $3.11      $5.94


    Weighted average common shares outstanding:

            Basic                                              59,073     58,606

            Diluted                                            60,887     61,448


                             NU SKIN ENTERPRISES, INC.

                      Consolidated Balance Sheets (Unaudited)

                         As of December 31, 2014 and 2013

                                  (in thousands)


                                                                 2014       2013
                                                                 ----       ----

    ASSETS

    Current assets:

            Cash and cash equivalents                        $288,415   $525,153

            Current investments                                11,793     21,974

            Accounts receivable                                35,834     68,652

            Inventories, net                                  338,491    339,669

            Prepaid expenses and other                        160,134    162,886
                                                              -------    -------

                                                              834,667  1,118,334


    Property and equipment, net                               464,783    396,042

    Goodwill                                                  112,446    112,446

    Other intangible assets,
     net                                                       75,062     83,168

    Other assets                                              127,476    111,072
                                                              -------    -------

                    Total assets                           $1,614,434 $1,821,062
                                                           ========== ==========


    LIABILITIES AND STOCKHOLDERS' EQUITY

    Current liabilities:

            Accounts payable                                  $34,712    $82,684

            Accrued expenses                                  300,847    626,284

            Current portion of long-
             term debt                                         82,770     67,824
                                                               ------     ------

                                                              418,329    776,792


    Long-term debt                                            164,567    113,852

    Other liabilities                                          89,100     71,799
                                                               ------     ------

            Total liabilities                                 671,996    962,443
                                                              -------    -------


    Stockholders' equity:

            Class A common stock                                   91         91

            Additional paid-in capital                        414,394    397,383

           Treasury stock, at cost                          (862,608) (826,904)

            Accumulated other
             comprehensive loss                              (51,521)  (46,228)

            Retained earnings                               1,442,082  1,334,277
                                                            ---------  ---------

                                                              942,438    858,619
                                                              -------    -------

                    Total liabilities and
                     stockholders' equity                  $1,614,434 $1,821,062
                                                           ========== ==========

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nu-skin-enterprises-reports-fourth-quarter-and-2014-results-300031332.html

SOURCE Nu Skin Enterprises, Inc.